A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker
Latest Information Update: 28 Aug 2023
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 16 Aug 2019 Status changed from active, no longer recruiting to discontinued.
- 29 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Jun 2018 Planned primary completion date changed from 1 May 2018 to 1 Jun 2019.